Murphy Pilar Z, Thomas Jimiece, McClelland Taylor P
Samford University McWhorter School of Pharmacy.
Innov Pharm. 2021 May 24;12(2). doi: 10.24926/iip.v12i2.3906. eCollection 2021.
Budd Chiari Syndrome (BCS) is a very rare disease affecting approximately 1 in 100,000 people in the general population. It is caused by an obstruction of the hepatic veins leading to blood backing up in the liver. Treatment options to improve hepatic blood flow and relieve ascites are well documented. However, there are no established guidelines or treatment preferences for pain associated with BCS while patients are awaiting other treatment options.
A 22-year-old African American female was diagnosed with Budd Chiari Syndrome. The initial attempt at a transjugular intrahepatic portosystemic shunt (TIPS) procedure failed. While awaiting a second attempt at the procedure, the patient presented to her primary care provider complaining of abdominal and right upper quadrant pain. Treatment guidelines were searched for acute pain management options; however, no BCS pain management guidelines exist.
Individuals with BCS often present with abdominal pain, however, no guidelines outlining analgesic options in BCS exists. Acetaminophen, NSAIDs, and opioids are commonly used prescription medications for moderate to severe pain. Acetaminophen use was not considered due to acute liver injury and portal venous thrombosis. Anticoagulation with apixaban prevented concurrent use with NSAIDs. Opioid medications combined with acetaminophen were excluded to minimize exacerbating the liver injury. Tramadol 25 mg was chosen due to its lower abuse profile than other opioid analgesics, and was initiated for pain management.
The patient reported adequate pain control with tramadol, tolerated the medication with no complications, and underwent a successful TIPS procedure one month later. Abdominal pain is a common symptom of BCS and needs to be effectively managed. Guidelines on treating pain associated with BCS in the outpatient setting would improve quality of life for patients and provide guidance to primary care providers requiring direction on how to address pain associated with Budd Chiari Syndrome safely and adequately.
布加综合征(BCS)是一种非常罕见的疾病,在普通人群中发病率约为十万分之一。它是由肝静脉阻塞导致血液在肝脏中淤积引起的。改善肝血流和缓解腹水的治疗方案已有充分记录。然而,在患者等待其他治疗方案期间,对于与布加综合征相关的疼痛,尚无既定的指南或治疗偏好。
一名22岁的非裔美国女性被诊断为布加综合征。经颈静脉肝内门体分流术(TIPS)的初次尝试失败。在等待再次进行该手术期间,患者向她的初级保健医生主诉腹痛和右上腹疼痛。查阅了治疗指南以寻找急性疼痛管理方案;然而,不存在布加综合征疼痛管理指南。
布加综合征患者常出现腹痛,然而,不存在概述布加综合征镇痛方案的指南。对乙酰氨基酚、非甾体抗炎药和阿片类药物是常用于治疗中度至重度疼痛的处方药。由于急性肝损伤和门静脉血栓形成,未考虑使用对乙酰氨基酚。使用阿哌沙班抗凝妨碍了与非甾体抗炎药同时使用。排除了阿片类药物与对乙酰氨基酚联合使用,以尽量减少加重肝损伤。选择曲马多25毫克是因为其滥用倾向低于其他阿片类镇痛药,并开始用于疼痛管理。
患者报告曲马多能有效控制疼痛,能耐受该药物且无并发症,并在一个月后成功接受了TIPS手术。腹痛是布加综合征的常见症状,需要有效管理。关于门诊治疗布加综合征相关疼痛的指南将改善患者的生活质量,并为需要指导如何安全、充分地处理布加综合征相关疼痛的初级保健医生提供指导。